The COVID-19 pandemic intensified site-access issues for patients, monitors and CRAs, accelerating the need for decentralised or virtual clinical trial solutions.

These disruptions have created new opportunities for sponsors to evaluate and evolve their technology strategy, prompting the leap into the next generation of hybrid clinical trials. But there is much to consider.

• Can you educate, enroll and ensure patient consent with virtual capabilities?
• Can you respond to urgent remote requirements for patients and sites?
• Will your strategy meet future standards for transforming trials?

Explore the eight parameters driving a successful approach to trial virtualisation. Download the eBook now.